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Abstract
Background. Conventional appraisal and reimbursement processes are being challenged by the
increasing number of rare disease treatments (RDTs) with a small evidence base and often a high
price. Processes to appraise RDTs vary across countries; some use standard processes, others have
separate processes or adapted processes that explicitly deal with rare disease specificities. The
objective of this study was to examine the impacts of different appraisal processes for two RDTs.
Methods. A case study analysis was conducted using countries with different forms of
appraisal processes for RDTs for which public health technology assessment (HTA) reports
were available. Two contrasting RDTs were chosen according to the criteria: rare versus
ultra-rare treatment, affecting child versus adult, life-threatening versus disabling.
Information from public HTA reports for each country’s RDT appraisal was extracted into
templates, allowing a systematic comparison of the appraisals across countries and identifica-
tion of the impact of the different processes in practice.
Results. Reports from Belgium, England, France, Germany, Italy, Netherlands, Norway,
Scotland, Sweden, and the USA were selected for nusinersen (for spinal muscular atrophy)
and voretigene neparvovec (for inherited retinal disorders). Countries with separate or
adapted processes had more consistent approaches for managing RDT-related issues during
appraisal, such as stakeholder involvement and criteria to address the specificities of RDTs,
creating more transparency in decision-making.
Conclusions. Findings suggest that separate or adapted approaches for RDT appraisal may facil-
itate more structured, consistent decision-making and better management of RDT specificities.
Background
Medicinal products to treat rare diseases fulfill a high unmet need for small populations suf-
fering from often severely debilitating or life-threatening illnesses (1). Although these rare dis-
ease treatments (RDTs) and ultra-RDTs (highly specialized treatments for very rare diseases)
hold promise to improve health and quality of life (QoL), they also pose considerable chal-
lenges for national health systems to appraise and reimburse, primarily because they come
with a substantial amount of evidential uncertainty and high costs (2). The uncertainties relat-
ing to determination of the value of RDTs stem from a number of challenges inherent to rare
diseases: they affect a small number of people, natural history knowledge is often limited, and
presentation is heterogeneous (3–6). Appraisal of RDTs often involves significant assumptions
about disease progression that cannot be validated, and reimbursement is often only possible
with a willingness to pay (WTP) that is above traditional thresholds. This raises the question as
to whether appraisal processes for RDTs should differ from standard ones (2;3;7–9).
In related research, we found that countries differ in their approaches to appraising RDTs
to determine clinical benefit and/or value for money. In some countries, standard appraisal
processes are used. In others, standard appraisal processes are adapted in order to better
deal with some of the common challenges encountered with RDTs or ultra-RDTs, and others
have entirely separate appraisal processes for RDTs or ultra-RDTs (10;11). Our previous work
characterized the features included in these separate or adapted appraisal processes for RDTs,
referred to from now as “supplemental.” Supplemental processes vary across countries and
include features such as different requirements for clinical and/or economic evidence, more
lenience around evidence quality, greater disease-specific input from patient and clinical
experts, additional considerations of value, different decision rules, different WTP thresholds,
or conditional approval (Supplementary Figure 1) (11).
This research was undertaken to enable a deeper understanding of how standard and
supplemental appraisal processes are implemented in practice for two RDTs and whether
the identified features of supplemental appraisal processes make a difference in the
decision-making.
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Methods
A case study design investigated the appraisal/reimbursement
processes for two RDTs across various countries with and without
supplemental processes for RDTs.
Country selection was based on availability of public health
technology assessment (HTA) reports and representative of coun-
tries with and without supplemental processes. The sample con-
sisted of three countries/country alliances using only standard
processes (the cross-border collaboration BeNeLuXAI, France,
and the Netherlands), five countries using only supplementary
processes (Belgium, Germany, Norway, Scotland, and Sweden),
and two countries having both standard and supplementary pro-
cesses, which were applied to one treatment or the other
(England, USA) (Table 1). All countries in Europe with supple-
mental processes were initially included, some of which were sub-
sequently excluded as they either did not have any publicly
available information or did not provide sufficient information
in their public reports (Italy, Lithuania, Poland, Romania, and
Slovakia). Because of the collaboration between countries that
are part of the BeNeLuXAI country alliance, BeNeLuXAI and
Belgium used the Netherland’s assessment, the only difference
being that for Belgium, an additional country-specific epidemiol-
ogy and budget impact analysis was conducted.
Two contrasting RDTs were sought: rare versus ultrarare treat-
ment (ultra-RDTs have even higher levels of uncertainty than
RDTs, and in some cases, differing country processes apply
only to ultra-RDTs), affecting child versus adult (as this aspect
often affects decisions), life-threatening versus disabling (acute,
often short-term treatment vs. longer-term treatment). A list of
potential RDT candidates was compiled based on desk research,
recommendations from country HTA experts, availability of
reports, and discussion among team members. This led to the fol-
lowing selection:
(1) nusinersen (Spinraza®): intrathecal injection every 4 months,
indicated for 5q spinal muscular atrophy (SMA) (children
and adults, life threatening in children, rare across all types).
(2) voretigene neparvovec (Luxturna®): one-off gene therapy,
indicated for RPE65-mediated inherited retinal dystrophies
(adults, long-term disabling, ultrarare).
HTA reports for nusinersen were retrieved for all 10 selected
jurisdictions and for eight of the 10 selected jurisdictions for vor-
etigene neparvovec (not available for Belgium or BeNeLuXAI).
The data from published HTA reports were extracted by coun-
try experts for Sweden and Norway and by AW for all other coun-
tries, using a template based on an existing methodological
framework (10). This framework provided a structure for data
extraction and analysis by distinguishing what occurred in the fol-
lowing stages of the appraisal process: (i) evidence considered, (ii)
interpretation of evidence, and (iii) pricing and reimbursement
decision, with the main focus on interpretation of evidence. The
framework enabled documentation of the appraisal/reimburse-
ment recommendation/decision, the clinical trials considered,
the main clinical and patient-reported endpoints, and a range
of issues that appeared to have influenced the appraisal. This sup-
ported reflection on the impact of the different types of appraisal
processes on decision making in each country. Results focus on
those cases identified where features from the supplemental pro-
cess (Supplementary Figure 1) were reported to impact the delib-
eration and/or where contrasts were seen across countries. To
illustrate the impact of these features, summaries of the key points
from the appraisal were extracted from the HTA reports and sup-
ported with direct quotes from the report text.
Results
Case Studies
Case Study #1: Nusinersen
SMA is a progressive condition caused by a missing gene that
weakens muscles and causes problems with movement, bones,
joints, and breathing. The most severe type affects babies (Type
1) and the least severe type affects adults (Type 4). The compar-
ator at the time nusinersen was appraised was best supportive care
(12). Physical debilitation reduces a person’s ability to live inde-
pendently. Babies with Type 1 rarely survive beyond the first
few years of life (13). Nusinersen compensates for the missing
gene that causes the condition. Treatment is continued as long
as it benefits patients. It is a designated orphan medicinal product
(OMP) in the EU and received marketing authorization under the
European Medicines Agency accelerated assessment program in
April 2017.
Case Study #2: Voretigene Neparvovec
Inherited retinal dystrophies (IRDs) are a group of rare genetic eye
diseases caused by gene mutations leading to progressive vision
loss. At the time of appraisal, the only comparator was supportive
care. It is a severe and progressive condition that affects all aspects
of patients’ lives in terms of independence, ability to work, social
life, and ability to carry out day-to-day tasks (14). Voretigene
neparvovec is a one-time gene therapy involving an injection in
each eye under the retina (14). It is an OMP that received market-
ing authorization in the EU in November 2018 for a specific pop-
ulation (15), which was considered as ultrarare or highly
specialized by HTA bodies that use that classification.
Appraisal Processes
The two selected RDTs underwent the standard appraisal process
in four countries, the supplemental process for RDTs in five
countries, and in two countries, one treatment underwent the
standard process and the other the supplemental RDT process
(England, US). Table 1 outlines the country processes and
further delineates the countries that focus on added clinical
benefit to determine reimbursement versus those that require
cost utility analysis (QALY-based). Further details about each
country’s appraisal process can be found on the IMPACT HTA
Web site (16).
The timing of the appraisal, reimbursement decision, and key
elements of countries’ appraisals are presented in Table 2. We
defined reimbursement decisions as “list” when it was granted
for the full indication submitted, with inclusion of a financial
managed entry agreement (MEA) in some cases; “conditional
approval” if an outcomes-based MEA was in place; “restrict” if
there were restrictions on use (e.g., restricted population or dis-
pensing); and “reject” when the decision was negative.
Most countries with and without special processes for RDTs
approved both treatments, some conditionally with an outcomes-
based MEA. However, we have explored in more depth what evi-
dence was considered, how it was interpreted by appraisal com-
mittees, and if any features of supplemental processes were
reported as being important for decision-making.
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Evidence Considered
In terms of the evidence considered by each country, only two
countries, both with supplemental processes, had different evi-
dence requirements for RDTs: Germany and Scotland. Scotland
has a different submission form for ultra-RDTs, whereas
Germany has a simplified process for RDTs and considers only
the pivotal trials. For both nusinersen and voretigene neparvovec,
it was not clear from the reports whether these differing evidence
requirements had any impact on the decision. In countries with
no differing evidence requirements, it was not clear from the
reports if or to what extent the additional trials considered by
some and not by others impacted the decision.
The clinical data considered by each country to inform their
appraisal processes can be found in Supplementary Table 1.
Interpretation of the Evidence
Issues Raised. A number of issues were reported during the delib-
erative process for the two treatments that related to uncertainties
in the clinical evidence and in the economic modeling. These
issues were dealt with differently across countries. Table 3 pre-
sents a summary of the reported issues raised by each country
for nusinersen and voretigene neparvovec (for the detailed list
of issues, see Supplementary Table 2).
Although the types of issues raised were not distinctively dif-
ferent between or dependent on whether the RDTs were assessed
through a standard or supplemental process, countries with sup-
plemental processes more often referred to explicit criteria to han-
dle such issues. In the HTA reports, each issue raised was not
specifically elaborated upon as to whether or not it was deemed
Table 1. Overview of appraisal/reimbursement processes used for nusinersen and voretigene neparvovec
Characteristics of country processes for appraising RDTs
Standard processes Supplemental processes
Non-QALY based
FRANCE (HAS): No special RDT process, but has accelerated option and
temporary access to medicine prior to receiving MA (not restricted to, but
likely applicable to RDTs).
GERMANY (G-BA): OMPs have guaranteed additional benefit and are
automatically reimbursed as long as company revenues do not exceed 50
million euros annually.
IQWIG is commissioned by G-BA to perform a benefit assessment when sales
volume of the product exceeds 50 million euro. This was not applicable to the
two chosen case studies.
QALY-based
BENELUXAI: A collaboration of countries with standard processes
(Belgium, Netherlands, Luxembourg, Ireland, and Austria), with the aim of
ensuring sustainable access and appropriate use of medicine. Cooperation
includes joint assessments.
BELGIUM (INAMI): Expedited process for OMPs; applicant does not have to
submit a pharmaco-economic model if considered to have added therapeutic
value (class 1).
ENGLAND (NICE)a: Single technology appraisal (STA): most RDTs go
through this route. Looks at benefit of the technology, impact on
health-related policy, impact on NHS resources, added value. End-of-life
criteria and reduced benefits discounting may be applied.
ENGLAND (NICE)a: Highly specialized technology program (HST) is a separate
process for ultra-RDTs requiring specialized commissioning. Considers nature
of condition; impact of technology; cost to the NHS/Personal services; value
for money; impact beyond direct health benefits; impact on specialized
services. Includes a different willingness-to-pay threshold, specialized
appraisal committee.
NETHERLANDS (Zorginstituut): No special RDT process, but aspects of
rarity are weighted in the decision (lower levels of evidence/more
uncertainty may be accepted when sufficient justification exists) as well as
severity and burden of disease.
NORWAY (NOMA): Special criteria considered for very rare and severe
conditions, with a potentially very effective treatment. Greater uncertainty
and higher ICER may be accepted.
U.S. (I.C.E.R.)b: Standard assessment pathway for RDTs (value
assessment framework); adaptations made to the value assessment
framework for ultra-RDTs in January 2020 (see right column).
SCOTLAND (SMC): UOMP framework: Designated treatments undergo
appraisal according to a broader decision-making framework.
UOMP pathway (since November 2019): Designated treatments are given
initial assessment according to the UOMP framework and provided for 3
years, with evidence generation, then appraisal.
Both include supplemental processes for OMPs: Patient And Clinician
Engagement meeting (PACE) if minded negative opinion for appraisal. Additional
criteria are accounted for beyond clinical and cost-effectiveness. Rarity included
as SMC modifier—greater uncertainty and higher WTP may be accepted.
SWEDEN (TLV): Special criteria considered for very rare and severe
conditions, with a potentially very effective treatment. Greater uncertainty
and higher ICER accepted.
U.S. (I.C.E.R.)b: Value assessment framework for ultra-RDTs adapted to
provide context and additional information about the distinctive nature of the
evidence and broader considerations relevant to decision-making.
Note: QALY-based systems consider economic models that include QALYs as measures of clinical benefit. Non-QALY based systems do not use QALYs as the preferred measure for clinical
benefit assessment and do not conduct any economic modeling.
OMP, orphan medicinal product; RDT designated by European Medicines Agency (EMA), ICER, Incremental Cost Effectiveness Ratio; WTP, Willingness to Pay.
aIn England, Nusinersen went through the standard (STA) pathway and Voretigene went through the HST pathway.
bThe (I.C.E.R.) recently implemented modifications to their Appraisal Framework that apply to ultra-RDTs. Nusinersen was assessed taking into account the ultra-RDT modifications.
Voretigene was assessed prior to the modifications and so is considered standard, but the report claims to take into account the framework adaptations.
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acceptable and why, although some selected issues were thor-
oughly discussed; these are exemplified in detail below. Notably,
when summarizing the interpretation of the evidence, countries
with supplemental processes often highlighted that there were
many issues, such as low evidence quality, uncertainty around
long-term effects, and higher ICERs than those normally
accepted, but generally referred to criteria enabling them to man-
age these issues through greater leniency in terms of evidence
quality or different WTP thresholds.
This relates to a supplemental process feature, more leniency
when judging the quality of evidence, and is reflected in Table 3,
in which more countries with supplemental processes addressed
the issues raised (represented by √ instead of X) by further
explanation, discussion, or considering it acceptable given the
particular circumstance. In particular, the general willingness to
accept greater uncertainty (last row of the table) was reported
more in countries with supplemental processes (1/4 standard
vs. 3/6 supplemental processes for nusinersen; 0/3 standard vs.
5/5 supplemental processes for voretigene neparvovec). The
way in which these elements were reported is highlighted in
the example report quotations below, first for countries with stan-
dard processes, followed by countries with supplemental pro-
cesses, for nusinersen and voretigene neparvovec, respectively.
For nusinersen, England (STA) was the only country using a
standard process that explicitly accepted greater uncertainty: “com-
mittee was prepared to take into account a wide range of factors…
concluded that it was willing to be flexible in its considerations
around uncertainty…”. From the countries using supplemental
processes, Scotland accepted greater clinical uncertainty in relation
to its decision-making criteria: “… a number of the criteria were
satisfied: the absence of other treatments of proven benefit and a
substantial improvement in life expectancy…”. Scotland similarly
accepted uncertainty in the economic evidence in relation to its
Table 2. (Continued.)
(Continued )
Table 2. Details of country decisions for nusinersen and voretigene neparvovec
Notes:
- Poland, Romania, and Slovakia all approved Nusinersen for use, but due to a lack of
sufficient information in publicly available reports, they are included only in the discussion.
- ICER is a base case without MEA.
- All appraised for the same indication listed in the disease/treatment description unless
otherwise stated.
Grey, standard process; White, supplemental process; UO, ultra-orphan; HTA, health
technology assessment; ICER, incremental cost effectiveness ratio; QALY, quality adjusted
life year; Zin, Zorginstituut; MEA, managed entry agreement; NHS, National Health Service;
SMA, spinal muscular atrophy; TC, transparency committee; NOK, Norwegian krone; SEK,
Swedish kronor; OMP, orphan medicinal product.
aSMC initial restriction: type 1 was most significantly improved according to evidence, but as
of July 2019, it was listed under the ultra-orphan pathway, and types 2 and 3 were also
reimbursed.
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Table 3. Summary of issues raised across countries for nusinersen and voretigene neparvovec
NUSINERSEN
(Continued )
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decision-making criteria by stating, “As nusinersen is an ultra-
orphan medicine, SMC can accept greater uncertainty in the eco-
nomic case.” Norway’s rationale for eventually accepting greater
uncertainty was discussed in reference to its criteria to account
for disease severity. “For very severe diseases with small patient pop-
ulations, less extensive documentation requirements can be
accepted.” Germany accepted greater uncertainty by granting auto-
matic reimbursement for OMPs.
VORETIGENE NEPARVOVEC
Grey, standard process; White, supplemental process.
X, issue considered but not addressed; √, issue considered and addressed.
Additional information: Addressed = it was discussed but further explained/countered/considered acceptable anyway, Not addressed = it was just raised.
Table 3. (Continued.)
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For voretigene neparvovec, only countries using supplemental
processes explicitly accepted greater uncertainty. England (HST)
accepted issues by referring to unmet need and rarity of the con-
dition, stating: “The committee was aware that there is a high
unmet need in this population because there are no current spe-
cific treatments available for this condition. It recognized that the
results of clinical trials were uncertain because of the small sample
size and limited follow up. However, it considered that the evi-
dence showed that voretigene neparvovec improved visual perfor-
mance and was likely to prevent disease progression…. ” Norway
accepted greater uncertainty in the evidence by referring to its
decision-making criteria: “…when assessing drugs for particu-
larly small groups of patients with very serious condition, a
lower requirement for documentation and a higher use of
resources compared to other measures can be accepted”.
Sweden accepted uncertainty based on rarity: “The uncertainties
in the documentation and the results presented by TLV are con-
sidered to be very high. However, these uncertainties should be
understood based on the rarity of the disease.” Germany accepted
greater uncertainty by automatic reimbursement for OMPs, and
Scotland through its ultra-OMP process, permitting three years
of reimbursement and further data collection.
Other Considerations. One of the supplemental RDT process fea-
tures identified in our previous work is “broader consideration of
value,” that is, considerations beyond clinical and cost-
effectiveness. In addition to the issues raised, both supplemental
and standard process countries reported other considerations dur-
ing the deliberative process for both treatments, but differed
somewhat in their approaches. Table 4 outlines the other consid-
erations that countries took into account and highlights if these
were raised by stakeholder input from patients and/or clinicians.
The most notable differences between the two treatments were
that, for nusinersen, more countries with supplemental processes
(6/6) took into account the impact on QoL of patients and carers
than countries with standard processes (2/4) (based on expert
input). For nusinersen and voretigene neparvovec, most countries
documented that they took the standard elements relating to rare
diseases into account, namely rarity, severity, and unmet need,
regardless of whether they used standard or supplemental pro-
cesses. For both treatments, innovative nature of treatment, nature
of the population, financial burden of condition, substantially
improved life expectancy, and impact on specialized services
were documented only by a few countries, with the latter being
more predominant in those with supplemental processes. The
descriptions and quotations below highlight examples of how
these considerations were raised across countries and what they
were.
Impact on Quality of Life of Patients and Carers. Regardless of
standard or supplemental process, the way this consideration
was addressed was quite uniform for both RDTs among countries:
“Some patients will be able to live longer with a significantly better quality
of life…” (nusinersen Norway).
Nature of the Population (Children).
“Considering… its beginning being either early after birth (severe forms
evolving rapidly), or later in childhood…” (voretigene neparvovec,
France).
Only France and England STA considered the nature of the pop-
ulation for nusinersen, but this is not explicitly outlined as a cri-
terion to consider in the decision-making process. However, in
NICE HST, the nature of the condition is one of the four parts
of the decision-making quadrant.
Rarity, Severity, and Unmet Need. Rarity, severity, and unmet
need were accounted for equally by countries using standard pro-
cesses and supplemental processes for nusinersen and voretigene
neparvovec:
“Committee acknowledged the difficulty of appraising drugs for very rare
conditions” (rarity, nusinersen, England STA).
Rarity is an explicit part of the assessment criteria in Germany
and the Netherlands, but not in the STA process in England,
yet the challenges relating to rarity were still considered in
England.
“SMA is a serious, progressive muscle disease” (severity, nusinersen,
Netherlands).
“Hereditary retinal dystrophy… is severe” (severity, voretigene neparvo-
vec, Norway).
Severity is an explicit part of the criteria in Belgium, Norway,
and Sweden for potentially accepting an ICER higher than tradi-
tional WTP levels. It was considered within England STA but is
not part of their criteria.
“At present there is no alternative to symptomatic treatment…” (unmet
need, nusinersen, BeNeLuXAI).
Innovative Nature of the Product. Regardless of the type of pro-
cess, some counties referred to the innovative nature of the prod-
uct for both treatments, and did so by referring to aspects that
could be considered to represent innovative nature:
“nusinersen has a novel mechanism of action…” (nusinersen, US).
Financial Burden of Condition. Was raised only by one country
with a standard process (England STA) and two countries with
a supplemental process (Scotland). The financial burden of the
condition is a criterion in Scotland’s appraisal process, but not
in England STA.
Impact on Specialized Services. Was raised only by four countries,
three with supplemental processes (England HST, Scotland, and
Sweden) and one with a standard process (France).
For a full list of quotations, see Supplementary Table 3.
Countries with supplemental processes more often referred to
criteria that enabled them to consider factors beyond clinical and
cost-effectiveness.
Stakeholder Input. For both nusinersen and voretigene neparvo-
vec, stakeholder input (patients, clinicians, or Scotland’s “patient
and clinician engagement meeting” (PACE)) played a role in rais-
ing some of the other considerations beyond clinical and cost-
effectiveness. The amount of stakeholder input was reported
more in countries with supplemental processes than in countries
with standard processes, which may be because countries with
supplemental processes are providing greater detail in their
reports.
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For nusinersen, England’s STA was the only standard process
that reported stakeholder input, whereas from the supplemental
process countries, Norway, Scotland, and the USA reported stake-
holder engagement. The structured PACE meeting in Scotland cap-
tured a wide range of value elements (Table 4), and of all countries
that accounted for stakeholder input, highlighted the most consid-
erations to provide context regarding disease and treatment. In
the supplemental processes of Norway and the USA, patients high-
lighted the impact on QoL, and in the USA, severity as well.
For voretigene neparvovec, stakeholder engagement high-
lighted more additional points of consideration in countries
with supplemental processes. Of the standard process countries,
only the USA reported stakeholder input in terms of influence
on QoL. Of the supplemental process countries, England HST,
Scotland, and Sweden reported stakeholder input.
Patient Reported Outcome Measures (PROMs). No differences
were seen in the use of PROMs between standard and
Table 4. Other considerations that contributed to the determination of value
√: other consideration mentioned in the HTA report.
P/C: other consideration mentioned in the HTA report raised by the patient (P) and/or clinical experts (C), or at a PACE meeting. Mod = Modifier: other consideration recognized as SMC
modifier for which greater uncertainty and higher cost/QALY threshold may be accepted. Nature of population: children and young people; PACE, patient and clinician engagement; QoL,
quality of life; substantially improved life expectancy relates to an “end of life” medicine, which is used to treat a condition that is at a stage that normally results in death in 3 years or less
with currently available treatments.
Gray, standard process; White, supplemental process.
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supplemental process countries, for either treatment. The only
differences were between countries with non-QALY based pro-
cesses (France and Germany) and those with QALY based pro-
cesses (all others). Given that they do not use cost-effectiveness
analysis, France and Germany only focused on PROMs for a
general, qualitative assessment of benefit for both treatments.
For nusinersen, PROMs were reported in the company sub-
mission in the form of the PedsQL questionnaire in the
CHERISH study, and all countries who use economic models
reported it as a factor in the deliberation (Belgium, BeNeLuXAI,
Netherlands, Norway, Scotland, Sweden, and the USA). EQ-5D
youth version was also considered in Sweden, which reported
these PROMs as being important for the decision.
For voretigene neparvovec, a visual function questionnaire was
submitted, along with vignettes. Regardless of having standard or
supplemental processes, all countries reported numerous uncer-
tainties with the PROM measures. For example, Germany noted
that validity was too unclear to take the PROMs into account,
and England noted that the lack of direct HRQoL measures was
a key limitation. From the public HTA reports, it seems there
were many limitations observed in the PROM data, such as a
lack of validity, uncertain utility values, or low response rates,
which might explain why QoL seemed to be more often consid-
ered during the deliberations based on input from patient and
clinical experts than from PROMs.
Pricing and Reimbursement Decision
A number of differences in the interpretation of the evidence
across countries were identified around the types of issues raised,
whether they were deemed acceptable, the consideration of expert
opinion, and other considerations. Despite these differences, most
countries accepted both treatments for full, restricted, or condi-
tional reimbursement. This can be further explained by the differ-
ent process features applied when making the decision, allowing
for different decision rules, conditional reimbursement to manage
uncertainty, greater WTP, or a combination thereof.
The supplemental RDT process feature of “different appraisal
rules for RDTs” was reported in two supplemental process coun-
tries, namely Germany and Scotland. For nusinersen and voreti-
gene neparvovec, automatically proven benefit was granted in
Germany due to its status as an OMP. In Scotland, voretigene
neparvovec was designated as an ultra-OMP and within the new
ultra-OMP pathway had an interim assessment that identified
uncertainties. A data collection plan was agreed with the Scottish
Government and a full appraisal will occur after three years.
Another feature of supplemental RDT processes is “differing
WTP,” usually represented by acceptance of an ICER that is
higher than traditional WTP thresholds. A higher WTP was
seen in countries with both supplemental and standard processes.
For nusinersen, in terms of standard process countries,
England STA accepted the higher ICER within the context of
implementing MEA: “the cost-effectiveness estimates… above
the range normally considered cost-effective…nusinersen should
be recommended… for the duration of and within the conditions
set out in the managed access arrangement.” From countries with
supplemental processes, for example in Scotland, decision modi-
fiers were applied and a higher WTP was accepted. Sweden stated
that “a higher cost per QALY can usually be accepted when the
severity is high or if there are few other treatments to choose
from.”
For voretigene neparvovec, in using its standard process,
I.C.E.R. in the USA stated that “for ultra-rare diseases, decision-
makers in the US… often give special weighting to other benefits
and to contextual considerations that lead to coverage and fund-
ing decisions at higher prices, and thus higher cost-effectiveness
ratios…”. This was seen in the considerations made in the
I.C.E.R. report regarding QoL, innovation, rarity, severity, and
unmet need. In using its supplemental process, England (HST)
stated: “The committee was satisfied that voretigene neparvovec
would offer significant QALY gains, and therefore applied this
weighting in its consideration of its value for money.”
Most countries accepted a higher than usual ICER and
approved both treatments, regardless of whether they used a stan-
dard or supplemental process. The rationale for this was often the
additional criteria considered and the negotiation of an MEA.
MEAs were also identified as a supplemental RDT process fea-
ture but were used as a way to deal with uncertainty by countries
with both supplemental and standard processes. For nusinersen,
Scotland’s ultra-RDT process required a three-year data genera-
tion period, followed by reassessment. England’s standard STA
process required a five-year MEA. Norway applied an MEA. For
voretigene neparvovec, a finance-based agreement was provided
in England (HST), and other countries made outcome-based
agreements.
Discussion
This analysis sought to examine the impacts of standard and sup-
plemental RDT appraisal processes in practice. Given two con-
trasting treatments, the differences in the decision-making
process for nusinersen and voretigene neparvovec were not imme-
diately obvious. For both treatments, standard and supplemental
process countries often reported many issues, made additional
considerations of value, and found ways to manage the high
price. For countries with standard and supplemental processes,
the following key points were observed:
(1) Only supplemental processes had different clinical or eco-
nomic submission requirements for RDTS: Germany and
Scotland. For Germany, this was the expedited process with-
out the initial IQWiG assessment. In Scotland, this allowed
presentation of evidence about wider aspects of value.
(2) Stakeholder input highlighted important factors in consider-
ation of value beyond clinical and cost-effectiveness more
often in countries with supplemental processes (England
HST, Norway, Scotland, Sweden, and the USA) for both
RDTs, particularly structured stakeholder input in the form
of the PACE meeting in Scotland.
(3) Different thresholds/decision frameworks were seen in coun-
tries with supplemental processes; many countries with sup-
plemental processes have formal criteria that allow acceptance
of an ICER that is higher than the usual WTP threshold.
(4) Countries with standard and supplemental processes did not
obviously differ in their reported assessments and consider-
ations, but this lack of clear differences may be due to the
fact that it was difficult to extract this information from the
HTA reports. With the exception of the NICE reports,
which clearly state what the “committee considered” for its
decision, it was not possible to judge from the other HTA
reports which considerations impacted the decision most.
This points to a need for better reporting of all considerations
relevant for the decision, as these are the only public facing
documents that can allow an understanding of how decisions
are made.
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(5) Stakeholder input can come from patient and clinical group
submissions, structured peer review comments on the evi-
dence, meetings with experts, and also from comments dur-
ing the appraisal; it was not always possible to differentiate
between these sources from the reported information, which
similarly points to a need for clearer reporting.
(6) For both treatments, only a few countries extended their con-
siderations beyond more conventional elements (i.e., QoL,
rarity, severity, and unmet need) to aspects such as the inno-
vative nature of the treatment, the nature of the population,
the financial burden of the condition, substantial improve-
ment in life expectancy, and impact on specialized services.
These are equally important and could be more frequently
taken into account alongside the more common
considerations.
(7) Although clear distinctions between countries were not obvi-
ous, countries with supplemental processes were more likely
to have formal criteria in place for addressing the specificities
of RDTs, and more often referred to this in their reports.
There were instances when countries with standard processes
also “applied” the features of supplemental processes. This
more informal consideration of RDTs may lead to less consis-
tent decision making in countries without supplemental
processes.
(8) It is relevant to note that financial agreements between man-
ufacturers and payers are confidential and we have no insight
into this. Although recommendations for reimbursement
were mostly positive for both treatments regardless of
whether a standard or supplemental process was used, we
cannot fully conclude the impact of the type of process on
the outcome. Supplemental processes may, for instance,
have had a different impact on the financial agreement than
standard processes, but this remains unknown.
This analysis highlights the complexity of the appraisal pro-
cesses for RDTs. It found that the previously identified features
of supplemental RDT processes do seem to be applied more in
countries with supplemental processes, but are also applied less
formally in countries with standard processes, which may lead
to more inconsistency. These features may have driven the delib-
erative process of appraisal differently for those countries with
supplemental processes, but this is unclear from reports. As a
result, another workstream in this research is undertaking ethno-
graphic observation of appraisal committees to further explore
what impacts decisions about RDTs.
Although we cannot determine from the HTA reports to what
degree these considerations factored into the decision itself, in
general, these elements of supplemental processes seem to enable
structured and consistent consideration of the specificities of each
rare disease and treatment during appraisal.
Strengths and Limitations
The strength of this research lies in enabling a deeper understand-
ing of how standard and supplemental RDT appraisal processes
play out in practice. To our knowledge, this is the first publication
to adopt the approach of comparing standard with supplemental
appraisal processes for RDTs. The investigation of a wide variety
of country HTA reports is unique, as many reports are in national
languages and not easily accessible without time and resources
investment to translate and understand the report contents.
As a result, these case studies provide invaluable insights into
the details of the HTA decision-making process for RDTs and a
reference point for understanding how various countries report
handling the appraisal of these treatments.
It is also important to note the limitation that the analysis was
based on publicly information provided in HTA reports, which
cannot capture the full picture of the appraisal process, but is
simultaneously a strength in that it highlights the degree of trans-
parency that HTA bodies demonstrate in reporting their decision-
making processes.
Additionally, a limited number of RDTs and countries were
examined based on feasibility, and both RDTs were accepted in
almost all included countries. A wider picture could be gained
by looking at more RDTs and more countries. With these case
studies, we explore possible explanations, but we cannot make
definitive statements about the reasons for country differences
as the public reports do not provide enough information to clearly
identify the key points that ultimately impacted decisions.
Conclusion
This analysis of public HTA reports illustrates how standard and
supplemental appraisal processes for RDTs are implemented.
Although in these case studies both RDTs were generally accepted
for full or conditional reimbursement, making it difficult to con-
clude how much of a difference supplemental processes make,
they do reflect the finding by Nicod et al. (11) that supplemental
RDT processes have a number of different mechanisms/more for-
mal criteria than standard processes, which can enable RDT spec-
ificities to be accounted for in the decision-making process. This
includes, for instance, differing evidence requirements for RDTs,
being more lenient around the quality of evidence and accepting
higher uncertainty, broader considerations, and a higher WTP
threshold. Such formal criteria may help more accurately appraise
the value and challenges of RDTs in a more structured way and
aid in consequent decisions being more transparent and
consistent.
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be found at https://doi.org/10.1017/S0266462321000337.
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